And the only knock on traditional MSCs in real-world application, when utilized appropriately, is they have an immunomodular modulatory immunoimmunity response, essentially, where 10 to 15% of people will get flu-like symptoms. And that's with traditional MSCs, which is a very low safety profile. What you saw, like effective safety profile, what you saw with the muse cells in trials is 0%. Literally right now, nobody's even getting flu-like symptoms.